

Nick Giannoukakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2568680/publications.pdf>

Version: 2024-02-01

37
papers

1,235
citations

623734

14
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

1362
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3483.	4.0	12
2	Modulation of Leukocytes of the Innate Arm of the Immune System as a Potential Approach to Prevent the Onset and Progression of Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 313-322.	0.6	9
3	Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-trans Retinoic Acid and Transforming Growth Factor Beta-1 Single Microparticle Formulation. <i>Frontiers in Immunology</i> , 2021, 12, 586220.	4.8	16
4	Autoimmune Inflammation and Insulin Resistance: Hallmarks So Far and Yet So Close to Explain Diabetes Endotypes. <i>Current Diabetes Reports</i> , 2021, 21, 54.	4.2	8
5	Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation. <i>Clinical Immunology</i> , 2015, 160, 103-123.	3.2	58
6	A brief glimpse over the horizon for type 1 diabetes nanotherapeutics. <i>Clinical Immunology</i> , 2015, 160, 36-45.	3.2	12
7	Nanotherapeutics for autoimmunity becomes mainstream. <i>Clinical Immunology</i> , 2015, 160, 1-2.	3.2	3
8	Evaluation of ranirestat for the treatment of diabetic neuropathy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1051-1059.	3.3	6
9	It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes. <i>Diabetes</i> , 2014, 63, 20-30.	0.6	50
10	Involvement of Suppressive B-Lymphocytes in the Mechanism of Tolerogenic Dendritic Cell Reversal of Type 1 Diabetes in NOD Mice. <i>PLoS ONE</i> , 2014, 9, e83575.	2.5	44
11	Retinoic acid-producing, ex vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B-lymphocytes. <i>Clinical and Experimental Immunology</i> , 2013, 174, n/a-n/a.	2.6	51
12	Interview: Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. <i>Immunotherapy</i> , 2013, 5, 919-921.	2.0	6
13	Tolerogenic dendritic cells for Type 1 diabetes. <i>Immunotherapy</i> , 2013, 5, 569-571.	2.0	13
14	A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2012, 19, 279-287.	2.3	31
15	Sequence Variation in Promoter of Ica1 Gene, Which Encodes Protein Implicated in Type 1 Diabetes, Causes Transcription Factor Autoimmune Regulator (AIRE) to Increase Its Binding and Down-regulate Expression. <i>Journal of Biological Chemistry</i> , 2012, 287, 17882-17893.	3.4	14
16	Dendritic cell therapy for Type 1 diabetes suppression. <i>Immunotherapy</i> , 2012, 4, 1063-1074.	2.0	15
17	Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity. <i>Immunologic Research</i> , 2011, 50, 130-152.	2.9	10
18	Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2011, 34, 2026-2032.	8.6	364

#	ARTICLE	IF	CITATIONS
19	Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-18.	3.3	24
20	Drug delivery technologies for autoimmune disease. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1279-1289.	5.0	4
21	Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. <i>Pediatric Diabetes</i> , 2008, 9, 4-13.	2.9	38
22	Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 575-581.	4.1	27
23	A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes. <i>Diabetes</i> , 2008, 57, 1544-1555.	0.6	91
24	BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 842-8.	2.3	4
25	Drug evaluation: ranirestat—an aldose reductase inhibitor for the potential treatment of diabetic complications. <i>Current Opinion in Investigational Drugs</i> , 2006, 7, 916-23.	2.3	12
26	Pyridoxamine (BioStratum). <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 410-8.	2.3	10
27	Gene therapy for type 1 diabetes: a proposal to move to the next level. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 467-75.	2.8	3
28	DiaPep277 (DeveloGen). <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 1043-50.	2.3	3
29	Antisense Oligonucleotides Down-Regulating Costimulation Confer Diabetes-Preventive Properties to Nonobese Diabetic Mouse Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 4331-4341.	0.8	161
30	Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 369-380.	5.7	6
31	Prevention of Diabetes in NOD Mice by Administration of Dendritic Cells Deficient in Nuclear Transcription Factor- κ B Activity. <i>Diabetes</i> , 2003, 52, 1976-1985.	0.6	86
32	Gene therapy technology applied to disorders of glucose metabolism: promise, achievements, and prospects. <i>BioTechniques</i> , 2003, 35, 122-145.	1.8	8
33	Exenatide. Amylin/Eli Lilly. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 459-65.	2.3	8
34	Fidarestat. Sanwa Kagaku/NC Curex/Sankyo. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 1233-9.	2.3	4
35	CJC-1131. ConjuChem. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 1245-9.	2.3	14
36	Gene and Cell Therapies for Diabetes Mellitus. <i>BioDrugs</i> , 2002, 16, 149-173.	4.6	8

#	ARTICLE	IF	CITATIONS
37	Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and prevention. Current Opinion in Investigational Drugs, 2002, 3, 735-51.	2.3	2